| Quarterly Financials | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 52 | 62 | 81 | 111 | 109 | 127 | 109 | 99 | 90 | 92 | 122 | 125 | 115 | 97 | 85 | 103 | 107 | 84 | 86 | 109 | 118 | 125 |
| Expenses | 41 | 54 | 56 | 84 | 81 | 88 | 81 | 77 | 73 | 79 | 103 | 112 | 93 | 76 | 73 | 83 | 93 | 78 | 79 | 99 | 100 | 101 |
| EBITDA | 11 | 8 | 25 | 27 | 28 | 39 | 29 | 22 | 17 | 13 | 19 | 14 | 22 | 21 | 12 | 20 | 14 | 6 | 7 | 10 | 19 | 23 |
| Operating Profit % | 20 % | 11 % | 31 % | 23 % | 24 % | 29 % | 23 % | 22 % | 17 % | 12 % | 15 % | 10 % | 19 % | 21 % | 13 % | 16 % | 12 % | 7 % | 8 % | 8 % | 15 % | 18 % |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 9 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit Before Tax | 8 | 6 | 23 | 24 | 24 | 35 | 26 | 19 | 14 | 9 | 14 | 8 | 13 | 11 | 5 | 14 | 7 | -1 | -0 | 2 | 9 | 14 |
| Tax | 2 | 2 | 2 | 3 | 1 | 3 | 3 | 2 | 4 | 2 | 3 | -9 | 4 | 3 | 2 | 4 | 2 | -0 | -0 | 1 | 3 | 4 |
| Net Profit | 7 | 4 | 21 | 21 | 23 | 32 | 23 | 18 | 10 | 7 | 12 | 17 | 10 | 8 | 4 | 10 | 5 | -1 | 0 | 1 | 7 | 10 |
| EPS in ₹ | 3.34 | 1.77 | 10.39 | 10.51 | 11.52 | 15.02 | 10.29 | 7.90 | 4.42 | 3.21 | 5.24 | 7.65 | 4.29 | 3.43 | 1.48 | 4.11 | 2.23 | -0.29 | 0.06 | 0.44 | 2.84 | 4.24 |
Tatva Chintan Pharma
Tatva Chintan Pharma
1,470.90
+18.40
(1.27%)
There are 1 new updates from the company19 hours ago
View
Key Fundamentals
Market Cap
3,440.74 Cr
EPS
2.44
PE Ratio
191.36
Dividend Yield
0.07 %
Industry
Chemicals 52 Week High
1,582.00
52 Week Low
621.00
PB Ratio
4.59
Debt to Equity
0.03
Sector
Specialty Chemicals Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
Tatva Chintan Pharma Chem Reports Strong Q2 Turnaround with 99.2 Million Rupees Net Profit
4 days ago
4 days agoTatva Chintan Pharma Chem delivered a significant turnaround in Q2 performance, reporting a consolidated net profit of 99.2 million rupees compared to a loss of 6.64 million rupees in the same period last year. The company's revenue grew substantially to 1.24 billion rupees from 835 million rupees year-over-year. EBITDA increased to 222 million rupees from 56 million rupees, while EBITDA margin expanded to 17.99% from 6.69% in the previous year's corresponding quarter.
Tatva Chintan Pharma Chem delivered a significant turnaround in its quarterly performance, posting a net profit of 99.2 million rupees compared to a loss of 6.64 million rupees in the same period last year. Revenue grew substantially to 1.24 billion rupees from 835 million rupees year-over-year. The company's EBITDA surged to 222 million rupees from 56 million rupees, while EBITDA margin expanded to 17.99% from 6.69% in the previous year.
Tatva Chintan Pharma Chem Clarifies Price Movement to Stock ExchangesOct 24, 2025
Tatva Chintan Pharma Chem Limited responded to inquiries from NSE and BSE regarding price movement in its equity shares. The company stated it has been complying with disclosure requirements and has not withheld any material information that would affect share price or volume behavior. The company attributed the price movement to market conditions and stated it is market driven.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,452.40 | #1 1,46,835.80 | 65.30 | 13,387.50 | 6.91 | #1 2,096 | 8.20 | 36.05 | |
2,877.70 | 85,942.40 | 53.16 | 14,825.80 | 12.13 | 1,251 | 92.75 | 38.25 | |
3,610.00 | 39,655.85 | 64.46 | 4,853.20 | 10.61 | 546 | 70.37 | 47.04 | |
5,974.00 | 31,138.20 | 70.13 | 2,393.10 | 12.83 | 289 | #1 152.38 | 83.10 | |
1,725.30 | 23,630.10 | 38.90 | 8,365.80 | 7.84 | 697 | -44.54 | 37.91 | |
4,372.80 | 18,927.94 | 48.07 | #1 15,339.40 | 10.81 | 479 | -37.72 | 39.03 | |
1,646.50 | 17,317.30 | 39.78 | 2,292.50 | 18.24 | 405 | 10.06 | 44.23 | |
5,701.50 | 16,959.90 | #1 30.17 | 5,692.40 | #1 18.99 | 499 | 30.75 | 37.60 | |
409.70 | 14,159.30 | 59.73 | 7,285.40 | 14.16 | 331 | 103.85 | 58.46 | |
4,367.70 | 13,391.36 | 32.44 | 2,366.70 | 7.83 | 411 | 3.35 | 33.14 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-3.99 %
Net Income Growth
-81.25 %
Cash Flow Change
-74.84 %
ROE
-81.31 %
ROCE
-82.30 %
EBITDA Margin (Avg.)
-49.74 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 0 | 188 | 249 | 315 | 658 | 759 | 819 | 836 |
| Fixed Assets | 0 | 67 | 111 | 120 | 160 | 196 | 427 | 526 |
| Current Assets | 0 | 114 | 133 | 184 | 436 | 312 | 298 | 265 |
| Capital Work in Progress | 0 | 6 | 5 | 10 | 52 | 231 | 77 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 |
| Other Assets | 0 | 115 | 133 | 185 | 447 | 332 | 305 | 283 |
| Total Liabilities | 0 | 188 | 249 | 315 | 658 | 759 | 819 | 836 |
| Current Liabilities | 0 | 73 | 88 | 118 | 171 | 239 | 80 | 96 |
| Non Current Liabilities | 0 | 35 | 44 | 31 | 14 | 5 | 2 | 1 |
| Total Equity | 0 | 80 | 118 | 166 | 473 | 515 | 737 | 739 |
| Reserve & Surplus | 0 | 72 | 110 | 146 | 451 | 493 | 714 | 715 |
| Share Capital | 0 | 8 | 8 | 20 | 22 | 22 | 23 | 23 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -10 | 8 | -5 | -6 | 59 | -36 | 8 | -24 |
| Investing Activities | -30 | -17 | -40 | -21 | -197 | -101 | -121 | -65 |
| Operating Activities | 13 | 7 | 25 | 20 | 20 | 28 | 98 | 25 |
| Financing Activities | 7 | 17 | 10 | -5 | 235 | 38 | 31 | 17 |
Share Holding
| % Holding | Jul 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 79.17 % | 75.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % | 72.02 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.41 % | 4.21 % | 3.65 % | 3.37 % | 3.33 % | 3.36 % | 3.30 % | 3.26 % | 3.39 % |
| DIIs | 5.52 % | 7.36 % | 7.78 % | 7.95 % | 10.56 % | 11.16 % | 11.52 % | 11.71 % | 11.07 % | 13.68 % | 13.79 % | 13.06 % | 12.84 % | 10.63 % | 6.82 % | 6.34 % | 5.46 % | 5.11 % | 3.86 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 9.89 % | 6.44 % | 6.62 % | 6.35 % | 6.03 % | 5.49 % | 5.01 % | 5.09 % | 5.91 % | 6.23 % | 8.72 % | 9.38 % | 10.49 % | 12.44 % | 15.95 % | 16.33 % | 16.92 % | 17.47 % | 18.29 % |
| Others | 5.42 % | 7.03 % | 6.43 % | 6.53 % | 4.24 % | 4.19 % | 4.31 % | 4.03 % | 3.85 % | 5.07 % | 1.06 % | 1.33 % | 1.00 % | 1.54 % | 1.87 % | 1.95 % | 2.30 % | 2.14 % | 2.44 % |
| No of Share Holders | 11 | 89,438 | 88,311 | 89,930 | 84,358 | 76,267 | 71,958 | 70,037 | 70,799 | 71,340 | 74,628 | 74,519 | 73,730 | 73,912 | 79,623 | 79,009 | 78,393 | 76,792 | 73,331 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 2 | 2 | 1 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.12 | 0.19 | 0.3 | 0.07 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Sept 2022 |  Dividend | ₹ 2.00 /share | 08 Sept 2022 | 2,478.80 | 2,480.20 |
| 08 Sept 2023 | Dividend | ₹ 2.00 /share | 08 Sept 2023 | 1,835.95 | 1,636.45 |
| 07 Sept 2024 | Dividend | ₹ 2.00 /share | 06 Sept 2024 | 1,228.15 | 972.95 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 1,000.80 | 972.05 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 1,002.00 | 949.30 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 843.90 | 814.75 |
| 02 May 2025 | Quarterly Result Announcement | NA | 02 May 2025 | 761.40 | 706.00 |
| 24 Jul 2025 | Quarterly Result Announcement | NA | 24 Jul 2025 | 944.95 | 997.40 |
| 12 Sept 2025 | Dividend | ₹ 1.00 /share | 12 Sept 2025 | 706.00 | 1,009.20 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 1,077.70 | 1,055.50 |
| 31 Oct 2025 | Quarterly Result Announcement | NA | 31 Oct 2025 | 1,286.10 | 1,356.50 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation13 minutes ago
13 minutes agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation18 minutes ago
18 minutes agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation23 minutes ago
23 minutes agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation19 hours ago
19 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation6 days ago
6 days agoIntimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements) Regulations 20156 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Change in Management6 days ago
6 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On 31.10.20256 days ago
6 days agoUnaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 20256 days ago
6 days agoClarification On Price MovementOct 24, 2025
Oct 24, 2025Clarification Sought from Tatva Chintan Pharma Chem LtdOct 23, 2025
Oct 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2025
Oct 17, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Friday 31.10.2025Oct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Intimation Of Record Date Book Closure And Cut-Off Date Pursuant To Regulation 42 And 44 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Aug 26, 2025
Aug 26, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Notice Of The 29Th AGM Of The Members Of The Company Scheduled To Be Held On Friday 26 September 2025 At 04:00 P.M. (IST) Through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM")Aug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Aug 12, 2025Communication To Shareholders - Dividend For FY 2024-25 - Intimation On Tax Deduction At Source (TDS) / Withholding Tax On DividendAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 24, 2025
Jul 24, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 24.07.2025Jul 24, 2025
Jul 24, 2025Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2025Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 17, 2025
Jul 17, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 24.07.2025Jul 17, 2025
Jul 17, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 07, 2025
Jul 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 05, 2025
Jul 05, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Credit RatingJun 17, 2025
Jun 17, 2025Clarification On Price MovementMay 23, 2025
May 23, 2025Clarification sought from Tatva Chintan Pharma Chem LtdMay 22, 2025
May 22, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Nippon India ELSS Tax Saver Fund Direct-Growth | 0.00% | -569970 | -0.38% | -0.40% | |
 ICICI Prudential MNC Fund Direct - Growth | 0.00% | -167937 | -1.01% | -1.03% | |
| ICICI Prudential Smallcap Fund Direct Plan-Growth | 0.00% | -97793 | -0.12% | -0.12% | |
| ICICI Prudential Commodities Fund Direct - Growth | 0.00% | -56748 | -0.19% | -0.20% | |
| Nippon India Small Cap Fund Direct- Growth | 0.00% | 0 | 0.00% | 0.00% | |
 SBI Mid Cap Direct Plan-Growth | 0.00% | 0 | 0.00% | 0.00% |
Technical Indicators
RSI(14)
Neutral 68.23
ATR(14)
Volatile 72.36
STOCH(9,6)
Neutral 69.56
STOCH RSI(14)
Neutral 44.78
MACD(12,26)
Bullish 11.15
ADX(14)
Strong Trend 47.61
UO(9)
Bearish 54.05
ROC(12)
Uptrend But Slowing Down 9.25
WillR(14)
Neutral -38.32
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
